We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Government Research Grant Approval for Quantum Immunologics

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Government Research Grant Approval for Quantum Immunologics"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
The total amount awarded is $646,000.00, which corresponds with the three development projects:

1. Dendritic cell therapy for treatment of breast cancer -- QI is developing an OFA/iLRP loaded autologous dendritic cell technology which represents a new therapeutic approach to the treatment of breast cancer utilizing the patient's own immune system.

2. Development of OFA/iLRP peptides for the treatment of cancer -- The development of OFA/iLRP peptides main goal is to provide a process improvement for our dendritic cell therapy. This technology represents a new therapeutic target to treat cancer utilizing the patient's own immune system.
3. Development of monoclonal antibodies against OFA/iLRP for the treatment and diagnosis of cancer -- This research is focused on utilizing monoclonal antibodies against specific peptide regions of the oncofetal antigen (OFA).

According to Chairman and CEO Chuck Broes, "The award of these grants represents an outstanding mark of achievement for QI's scientific endeavors. In addition, QI's shareholder base should feel very confident about the further strengthening of its financial position. This award provides the Company with significant funds that not only bolsters its operating capital but is also non-dilutive to our existing shareholders."